# A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

> **NCT04580498** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 107 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** SHR-1701+Paclitaxel+carboplatin
- **DRUG:** SHR-1701

## Key facts

- **NCT ID:** NCT04580498
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-10
- **Primary completion:** 2023-07-15
- **Final completion:** 2025-03-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2023-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04580498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04580498, "A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04580498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*